The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

GSK’s blood cancer drug Blenrep has been reapproved by the EU medicines regulator after it was removed from sale in 2023 because a trial failed to show it was superior to other treatments.

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.

The European Union has given regulatory approval to GSK's drug, Blenrep, for treating relapsed or treatment-resistant forms of blood plasma cell cancer.

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...